Does the media prefer SNSE or FTLF?

In the previous week, Sensei Biotherapeutics had 2 more articles in the media than FitLife Brands. MarketBeat recorded 5 mentions for Sensei Biotherapeutics and 3 mentions for FitLife Brands. FitLife Brands' average media sentiment score of 0.39 beat Sensei Biotherapeutics' score of 0.28 indicating that FitLife Brands is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sensei Biotherapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral FitLife Brands 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is ANIX or SNSE more profitable?

Anixa Biosciences' return on equity of -70.95% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Anixa Biosciences N/A -70.95% -62.53% Sensei Biotherapeutics N/A -83.59% -256.50%

Does the media favor ANIX or SNSE?

In the previous week, Sensei Biotherapeutics had 3 more articles in the media than Anixa Biosciences. MarketBeat recorded 5 mentions for Sensei Biotherapeutics and 2 mentions for Anixa Biosciences. Anixa Biosciences' average media sentiment score of 0.63 beat Sensei Biotherapeutics' score of 0.28 indicating that Anixa Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anixa Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sensei Biotherapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, ALDX or SNSE?

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aldeyra Therapeutics N/A N/A -$33.85M -$0.46 N/A Sensei Biotherapeutics N/A N/A -$21.08M -$142.72 N/A

Is ALDX or SNSE more profitable?

Aldeyra Therapeutics' return on equity of -57.34% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aldeyra Therapeutics N/A -57.34% -36.33% Sensei Biotherapeutics N/A -83.59% -256.50%

Does the media favor ALDX or SNSE?

In the previous week, Aldeyra Therapeutics had 2 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 7 mentions for Aldeyra Therapeutics and 5 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 0.28 beat Aldeyra Therapeutics' score of 0.20 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aldeyra Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sensei Biotherapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, SNSE or EDSA?

Edesa Biotech is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sensei Biotherapeutics N/A N/A -$21.08M -$142.72 N/A Edesa Biotech N/A N/A -$7.19M -$1.34 N/A

Is SNSE or EDSA more profitable?

Sensei Biotherapeutics' return on equity of -83.59% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Sensei Biotherapeutics N/A -83.59% -256.50% Edesa Biotech N/A -286.52% -75.36%

Sensei Biotherapeutics (SNSE) Competitors

$16.60 +0.75 (+4.73%)

Closing price 04:00 PM Eastern

Extended Trading

$16.60 0.00 (0.00%)

As of 04:10 PM Eastern

Compare

SNSE vs. FTLF, UPXI, ANIX, ALDX, and EDSA

Should you buy Sensei Biotherapeutics stock or one of its competitors? MarketBeat compares Sensei Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sensei Biotherapeutics include FitLife Brands (FTLF), Upexi (UPXI), Anixa Biosciences (ANIX), Aldeyra Therapeutics (ALDX), and Edesa Biotech (EDSA). These companies are all part of the "pharmaceutical products" industry.

How does Sensei Biotherapeutics compare to FitLife Brands?

Sensei Biotherapeutics (NASDAQ:SNSE) and FitLife Brands (NASDAQ:FTLF) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 2.3% of FitLife Brands shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Comparatively, 61.4% of FitLife Brands shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

FitLife Brands has a net margin of 6.64% compared to Sensei Biotherapeutics' net margin of 0.00%. FitLife Brands' return on equity of 18.31% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-83.59%	-256.50%
FitLife Brands	6.64%	18.31%	8.21%

FitLife Brands has higher revenue and earnings than Sensei Biotherapeutics. Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A
FitLife Brands	$81.46M	1.15	$6.33M	$0.60	16.57

In the previous week, Sensei Biotherapeutics had 2 more articles in the media than FitLife Brands. MarketBeat recorded 5 mentions for Sensei Biotherapeutics and 3 mentions for FitLife Brands. FitLife Brands' average media sentiment score of 0.39 beat Sensei Biotherapeutics' score of 0.28 indicating that FitLife Brands is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sensei Biotherapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
FitLife Brands	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Sensei Biotherapeutics currently has a consensus target price of $46.25, indicating a potential upside of 184.27%. FitLife Brands has a consensus target price of $21.50, indicating a potential upside of 116.30%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Sensei Biotherapeutics is more favorable than FitLife Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Sensei Biotherapeutics has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market. Comparatively, FitLife Brands has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market.

Summary

FitLife Brands beats Sensei Biotherapeutics on 10 of the 15 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Upexi?

Sensei Biotherapeutics (NASDAQ:SNSE) and Upexi (NASDAQ:UPXI) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Sensei Biotherapeutics currently has a consensus price target of $46.25, indicating a potential upside of 184.27%. Upexi has a consensus price target of $8.33, indicating a potential upside of 716.99%. Given Upexi's stronger consensus rating and higher probable upside, analysts clearly believe Upexi is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Sensei Biotherapeutics has a net margin of 0.00% compared to Upexi's net margin of -874.00%. Upexi's return on equity of -66.70% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-83.59%	-256.50%
Upexi	-874.00%	-66.70%	-19.56%

In the previous week, Sensei Biotherapeutics had 5 more articles in the media than Upexi. MarketBeat recorded 5 mentions for Sensei Biotherapeutics and 0 mentions for Upexi. Upexi's average media sentiment score of 1.89 beat Sensei Biotherapeutics' score of 0.28 indicating that Upexi is being referred to more favorably in the news media.

Company	Overall Sentiment
Sensei Biotherapeutics	Neutral
Upexi	Very Positive

Upexi has higher revenue and earnings than Sensei Biotherapeutics. Upexi is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A
Upexi	$15.81M	4.53	-$13.68M	-$0.62	N/A

Sensei Biotherapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market. Comparatively, Upexi has a beta of -0.35, suggesting that its share price is 135% less volatile than the broader market.

10.5% of Sensei Biotherapeutics shares are held by institutional investors. Comparatively, 5.7% of Upexi shares are held by institutional investors. 7.0% of Sensei Biotherapeutics shares are held by insiders. Comparatively, 9.0% of Upexi shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Upexi beats Sensei Biotherapeutics on 10 of the 16 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Anixa Biosciences?

Anixa Biosciences (NASDAQ:ANIX) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, Sensei Biotherapeutics had 3 more articles in the media than Anixa Biosciences. MarketBeat recorded 5 mentions for Sensei Biotherapeutics and 2 mentions for Anixa Biosciences. Anixa Biosciences' average media sentiment score of 0.63 beat Sensei Biotherapeutics' score of 0.28 indicating that Anixa Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anixa Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sensei Biotherapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anixa Biosciences has higher revenue and earnings than Sensei Biotherapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	418.33	-$10.93M	-$0.33	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A

Anixa Biosciences currently has a consensus target price of $8.50, suggesting a potential upside of 224.43%. Sensei Biotherapeutics has a consensus target price of $46.25, suggesting a potential upside of 184.27%. Given Anixa Biosciences' higher possible upside, research analysts clearly believe Anixa Biosciences is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Anixa Biosciences has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market.

Anixa Biosciences' return on equity of -70.95% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-70.95%	-62.53%
Sensei Biotherapeutics	N/A	-83.59%	-256.50%

Summary

Anixa Biosciences beats Sensei Biotherapeutics on 10 of the 14 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Aldeyra Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

59.7% of Aldeyra Therapeutics shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 11.8% of Aldeyra Therapeutics shares are held by company insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Aldeyra Therapeutics' return on equity of -57.34% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-57.34%	-36.33%
Sensei Biotherapeutics	N/A	-83.59%	-256.50%

Aldeyra Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 212.50%. Sensei Biotherapeutics has a consensus price target of $46.25, suggesting a potential upside of 184.27%. Given Aldeyra Therapeutics' higher possible upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Aldeyra Therapeutics had 2 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 7 mentions for Aldeyra Therapeutics and 5 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 0.28 beat Aldeyra Therapeutics' score of 0.20 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aldeyra Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sensei Biotherapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aldeyra Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market.

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A

Summary

Aldeyra Therapeutics beats Sensei Biotherapeutics on 8 of the 13 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Edesa Biotech?

Sensei Biotherapeutics (NASDAQ:SNSE) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

Sensei Biotherapeutics' return on equity of -83.59% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-83.59%	-256.50%
Edesa Biotech	N/A	-286.52%	-75.36%

In the previous week, Sensei Biotherapeutics had 5 more articles in the media than Edesa Biotech. MarketBeat recorded 5 mentions for Sensei Biotherapeutics and 0 mentions for Edesa Biotech. Sensei Biotherapeutics' average media sentiment score of 0.28 beat Edesa Biotech's score of -0.52 indicating that Sensei Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Sensei Biotherapeutics	Neutral
Edesa Biotech	Negative

Sensei Biotherapeutics currently has a consensus target price of $46.25, indicating a potential upside of 184.27%. Edesa Biotech has a consensus target price of $5.00, indicating a potential downside of 29.48%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Sensei Biotherapeutics is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Sensei Biotherapeutics has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

Edesa Biotech is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

10.5% of Sensei Biotherapeutics shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 7.0% of Sensei Biotherapeutics shares are held by insiders. Comparatively, 24.4% of Edesa Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Sensei Biotherapeutics beats Edesa Biotech on 8 of the 13 factors compared between the two stocks.

Get Sensei Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNSE vs. The Competition

Export

Metric	Sensei Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$21.80M	$3.34B	$6.44B	$12.46B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-0.11	18.78	23.87	24.36
Price / Sales	N/A	320.80	521.52	117.07
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	1.10	6.80	9.99	6.73
Net Income	-$21.08M	$24.09M	$3.56B	$337.03M
7 Day Performance	-7.50%	-2.56%	-0.89%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	131.04%	48.90%	28.77%	33.98%

Sensei Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNSE Sensei Biotherapeutics	2.8559 of 5 stars	$16.60 +4.7%	$46.25 +178.6%	+134.4%	$22.24M	N/A	N/A	40	News Coverage Analyst Forecast Insider Trade Gap Down
FTLF FitLife Brands	4.5516 of 5 stars	$9.93 -1.4%	$21.50 +116.5%	-30.3%	$94.57M	$81.46M	16.44	20
UPXI Upexi	3.0767 of 5 stars	$1.30 -3.0%	$8.33 +541.0%	-90.8%	$94.15M	$15.81M	N/A	130	Positive News
ANIX Anixa Biosciences	2.3916 of 5 stars	$2.73 -2.2%	$8.50 +211.4%	-10.6%	$93.54M	$210K	N/A	5
ALDX Aldeyra Therapeutics	3.3347 of 5 stars	$1.78 +14.8%	$5.50 +209.0%	-20.9%	$93.50M	N/A	N/A	10	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNSE) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sensei Biotherapeutics (SNSE) Competitors

SNSE vs. FTLF, UPXI, ANIX, ALDX, and EDSA

How does Sensei Biotherapeutics compare to FitLife Brands?

Summary

How does Sensei Biotherapeutics compare to Upexi?

Summary

How does Sensei Biotherapeutics compare to Anixa Biosciences?

Summary

How does Sensei Biotherapeutics compare to Aldeyra Therapeutics?

Summary

How does Sensei Biotherapeutics compare to Edesa Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNSE vs. The Competition

Sensei Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sensei Biotherapeutics (SNSE) Competitors

SNSE vs. FTLF, UPXI, ANIX, ALDX, and EDSA

How does Sensei Biotherapeutics compare to FitLife Brands?

Do institutionals & insiders have more ownership in SNSE or FTLF?

Is SNSE or FTLF more profitable?

Which has preferable earnings & valuation, SNSE or FTLF?

Does the media prefer SNSE or FTLF?

Do analysts recommend SNSE or FTLF?

Which has more risk & volatility, SNSE or FTLF?

Summary

How does Sensei Biotherapeutics compare to Upexi?

Do analysts recommend SNSE or UPXI?

Is SNSE or UPXI more profitable?

Does the media refer more to SNSE or UPXI?

Which has preferable earnings & valuation, SNSE or UPXI?

Which has more risk and volatility, SNSE or UPXI?

Do institutionals and insiders have more ownership in SNSE or UPXI?

Summary

How does Sensei Biotherapeutics compare to Anixa Biosciences?

Does the media favor ANIX or SNSE?

Which has better earnings and valuation, ANIX or SNSE?

Do analysts recommend ANIX or SNSE?

Do insiders and institutionals have more ownership in ANIX or SNSE?

Which has more volatility and risk, ANIX or SNSE?

Is ANIX or SNSE more profitable?

Summary

How does Sensei Biotherapeutics compare to Aldeyra Therapeutics?

Do institutionals & insiders hold more shares of ALDX or SNSE?

Is ALDX or SNSE more profitable?

Do analysts recommend ALDX or SNSE?

Does the media favor ALDX or SNSE?

Which has more risk & volatility, ALDX or SNSE?

Which has preferable valuation and earnings, ALDX or SNSE?

Summary

How does Sensei Biotherapeutics compare to Edesa Biotech?

Is SNSE or EDSA more profitable?

Does the media refer more to SNSE or EDSA?

Do analysts rate SNSE or EDSA?

Which has more risk and volatility, SNSE or EDSA?

Which has higher earnings and valuation, SNSE or EDSA?

Do institutionals & insiders have more ownership in SNSE or EDSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNSE vs. The Competition

Sensei Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools